Latest Sarepta Therapeutics News & Updates

See the latest news and media coverage for Sarepta. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sarepta Therapeutics (Sarepta)

Biotechnology company developing genetic medicines for rare diseases

sarepta.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 500–1,200
Industry: Pharmaceuticals

Last updated Today

Latest news about Sarepta Therapeutics (Sarepta)

In short: Sarepta appointed Michael Severino as CEO and achieved operating profitability despite challenges with its Elevidys gene therapy.

Company announcements

August 5 Sarepta

Sarepta reports Q2 2026 financial results and updates R&D progress

Revenue falls 34% to $401M while new CEO Michael Severino takes charge. The company narrows FY guidance and highlights pivotal trial milestones for ELEVIDYS and siRNA programs.

July 27 Sarepta

Sarepta appoints Michael Severino as CEO

Severino joins the Board succeeding Doug Ingram who retires after guiding Sarepta through significant growth and therapeutic approvals.

July 22 Sarepta

Sarepta to announce second quarter 2026 financial results after market close on August 5

The company will host a conference call at 4:30 p.m. E.T. to discuss the findings for stakeholders and investors.

June 30 Sarepta

Sarepta announces FDA acceptance of sNDAs

The agency sets a PDUFA target date of February 28, 2027. Submissions seek traditional approval for AMONDYS 45 and VYONDYS 53.

Media coverage

September 8 MSN

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Sarepta Therapeutics Inc. SRPT stock is trading lower on Tuesday in reaction to Novartis AG’s NVS data from the global Phase 3 HARBOR study of...

August 5 Yahoo Finance

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Other adverse reactions that occurred ... oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture. Other adverse...

July 27 STAT

Sarepta names Michael Severino, former Tessera CEO, as new chief executive

The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.

July 26 The Globe and Mail

Sarepta Therapeutics Appoints Michael Severino as CEO

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

Never miss news about Sarepta

Track Sarepta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sarepta competitors & trending companies

Browse news for competitors to Sarepta and other trending companies.